A proportion of patients with lung cancer experience long-term clinical benefit with immune
checkpoint inhibitors (ICIs). However, most patients develop disease progression during …

The emergence of immune checkpoint blockade therapies over the last decade has
transformed cancer treatment in a wide range of tumor types. Unprecedented and durable …

Metastatic disease is responsible for approximately 90% of cancer deaths. For successful
dissemination and metastasis, cancer cells must evade detection and destruction by the …

T Regulatory cells (Tregs) can have both protective and pathological roles. They maintain
immune homeostasis and inhibit immune responses in various diseases, including cancer …

Cancer immunotherapy can induce long lasting responses in patients with metastatic
cancers of a wide range of histologies. Broadening the clinical applicability of these …

Despite the high long-term survival in localized prostate cancer, metastatic prostate cancer
remains largely incurable even after intensive multimodal therapy. The lethality of advanced …

The heterogeneous nature of tumour microenvironment (TME) underlying diverse treatment
responses remains unclear in nasopharyngeal carcinoma (NPC). Here, we profile 176,447 …

Tumor-infiltrating lymphocytes (TILs) are an important histopathologic feature of colorectal
cancer that confer prognostic information. Previous clinical and epidemiologic studies have …

During the past decade, an abundance of new evidence highlighted the importance of
inflammation in the development of chronic pathologies such as neurodegeneration, cancer …

The use of inhibitory checkpoint blockade in the management of glioblastoma has been
studied in both preclinical and clinical settings. TIGIT is a novel checkpoint inhibitor recently …